Cardiovascular risk reduction in chronic myeloid leukemia patients treated with the tyrosine kinase inhibitors

• N. Lopina,
• I. Dmytrenko,
• D. Lopin,
• D. Hamov,
• I. Dyagil

Affiliations

N. Lopina

LLC “MED INFORM GROUP”, Kharkiv, Ukraine; Corresponding author.

I. Dmytrenko

National Scientific Center of Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Department of Radiation Oncohematology and Stem Cell Transplantation, Kyiv, Ukraine

D. Lopin

SI “V. T. Zaitsev Institite of General and Urgent Surgery of NAMS of Ukraine”, Kyiv, Ukraine

D. Hamov

“Cherkasy Regional Oncology Dispensary” of Cherkasy Regional Council, Regional Medical Hematology Center, Cherkasy, Ukraine

I. Dyagil

National Scientific Center of Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Department of Radiation Oncohematology and Stem Cell Transplantation, Kyiv, Ukraine